Previous 10 | Next 10 |
home / stock / tkphf / tkphf news
Shares of Wave Life Sciences (NASDAQ: WVE) , a clinical-stage biopharmaceutical, are plunging after the company closed the doors on its lead program. Suvodirsen flopped in a clinical trial, causing the stock to lose 53.7% as of 12:56 p.m. EST on Monday. Wave Life Sciences is developing ...
Takeda Pharmaceutical Co. Ltd. (TKPHF) Q3 2019 Results Earnings Conference Call October 31, 2019 08:00 AM ET Company Participants Takashi Okubo - IR Christophe Weber - CEO Constantine Saroukos - CFO Andrew Plump - President of R&D Conference Call Participants Josh b...
Takeda Pharmaceutical ( OTCPK:TKPHF ): 1H Non-GAAP EPS of ¥244.00; GAAP EPS of ¥21.00. More news on: Takeda Pharmaceutical Company Limited, Takeda Pharmaceutical Company Limited, Earnings news and commentary, Healthcare stocks news, Read more ...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) dipped steadily last week, falling from 3,310.52 points on Monday’s (September 23) open to 3,130.77 points as of 1:14 p.m. EDT on Friday (September 27). AzurRx BioPharma (NASDAQ: AZRX ) took a hit on Wednesday (September 25) after th...
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) , a clinical-stage biotech focused on treating rare diseases, popped after the company announced the appointment of a new board member. The stock jumped 15.7% higher in midday trading and ended Monday's session with a 12.9% gain. Investor-rel...
− Takeda UK Ltd. is pleased to announce that NICE has recommended the use of Takhzyro® (lanadelumab) subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE) in people aged 12 and older, within ...
BioCryst Pharmaceuticals, Inc.'s ( BCRX ) shares tanked more than 50% on May 21, 2019, after the company announced that it had met primary endpoints in the phase 3 trial of lead candidate BCX7353, a compound designed to be a once-daily orally administered capsule to prevent hereditary angioe...
The Collaboration As a large-cap ($51.9B) biopharma developing innovative therapeutics for diverse chronic diseases affecting different organ systems, Takeda Pharmaceuticals ( OTCPK:TKPHF ) ( TAK ) was expected to jump on the NASH bandwagon. In Q4/2017, Takeda initiated the first stage of ...
Takeda Pharmaceutical Company Limited (TKPHF) Q1 2019 Earnings Conference Call July 31, 2019, 05:00 PM ET Company Participants Takashi Okubo - Global Head of IR Christophe Weber - CEO Costa Saroukos - CFO Andy Plump - Chief Medical & Scientific Officer and Director Confe...
The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with their 2019 Q1 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Co Ltd Company Name:
TKPHF Stock Symbol:
OTCMKTS Market:
Takeda Pharmaceutical Co Ltd Website:
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...
JD.com Inc. (JD) is expected to report $0.56 for Q1 2024 Volkswagen AG (VLKAF) is expected to report for Q1 2024 CalAmp Corp. (CAMP) is expected to report for Q4 2024 Sonic Foundry Inc. (SOFO) is expected to report for Q2 2024 Moatable Inc ADR (R2RS:MU) is expected to report for Q...